{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974941",
  "id": "02974941",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250731",
  "time": "0902",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mc1pcjz77pym.pdf",
  "summary": "- **Partnership Announcement**: NeuroScientific transfers proprietary StemSmart\u2122 manufacturing process to Q-Gen Cell Therapeutics (QIMR Berghofer), a TGA-licensed cell therapy manufacturer.  \n- **Strategic Impact**: Enables scale-up of GMP-compliant production for clinical trials and commercial expansion, targeting Crohn\u2019s disease and graft-versus-host disease.  \n- **Technology**: StemSmart\u2122 is an allogeneic mesenchymal stromal cell platform with demonstrated efficacy in severe inflammatory conditions.  \n\n*No capital markets or trading-specific actions (e.g., raises, halts) identified.*",
  "usage": {
    "prompt_tokens": 1351,
    "completion_tokens": 121,
    "total_tokens": 1472,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T23:20:10.404926"
}